Filing summary
Entity discrepancy: The request identifies Talphera, Inc., but the supplied Form 10-Q is for AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX). This summary covers the filing provided, for the quarter ended September 30, 2020; it should not be treated as a Talphera filing summary.
Business context and reporting period
AcelRx is a specialty pharmaceutical company developing and commercializing therapies for medically supervised settings. Its portfolio includes U.S.-marketed DSUVIA, European-approved DZUVEO, and Zalviso, which is marketed in Europe and remains under development for U.S. approval. Financial statements are unaudited; amounts below are in U.S. dollars unless indicated.
Financial and operating performance
| Metric | Q3 2020 | Nine months 2020 | Comparable 2019 period |
|---|---|---|---|
| Total revenue | $1.37 million | $4.68 million | $0.61 million; $1.81 million |
| Product sales | $1.29 million | $1.86 million | $0.56 million; $1.45 million |
| Operating loss | $9.04 million | $31.72 million | $13.53 million; $39.21 million |
| Net loss | $8.93 million | $31.46 million | $12.73 million; $38.82 million |
| Basic and diluted loss per share | $0.10 | $0.38 | $0.16; $0.49 |
Q3 product sales included $935,000 of DSUVIA and $352,000 of Zalviso. Nine-month sales were $1.09 million and $772,000, respectively. Cost of goods sold exceeded total revenue by approximately $483,000 in Q3 and $54,000 year to date; the filing does not present a conventional positive gross margin for these periods.
- Operating expenses were $10.41 million in Q3 and $36.40 million for nine months, versus $14.14 million and $41.03 million a year earlier. Lower selling, general and administrative costs were the main reduction.
- Revenue growth included a one-time $2.57 million recognition of deferred revenue after Grünenthal’s termination of its agreements; nine-month revenue comparisons are therefore affected by this unusual item.
- Cash, cash equivalents and short-term investments totaled $43.02 million at September 30, down from $66.14 million at December 31, 2019. Current assets were $47.80 million and current liabilities $16.56 million.
- Operating cash use was $32.18 million for nine months, compared with $37.03 million in 2019. Investing activities provided $28.36 million, primarily from investment maturities; financing activities provided $9.10 million, including equity proceeds.
- Long-term debt, including current portion, was $23.71 million on the balance sheet; the company reported an accrued Oxford loan balance of $22.9 million. Separately, the liability related to the sale of future royalties was $89.34 million.
- Stockholders’ deficit was $57.85 million and accumulated deficit was $429.57 million. Shares outstanding rose to 90.48 million from 79.57 million at year-end, including a July offering of 9.43 million shares that generated about $10.0 million net.
Material changes, outlook and risks
- Commercial arrangements: Grünenthal’s Zalviso collaboration and supply agreements were scheduled to terminate November 13, 2020, with European and other territory rights reverting to AcelRx. No replacement license was in place at the filing date. AcelRx remains obligated to use commercially reasonable efforts to negotiate one.
- Sales partnerships: Zimmer Biomet Dental received U.S. DSUVIA distribution rights for specified dental and surgical channels. A promotion agreement with La Jolla, effective September 30, 2020, replaced the Tetraphase co-promotion arrangement and provides for a revenue share on covered DSUVIA sales.
- COVID-19: Restricted access to hospitals and surgical centers curtailed promotion and was expected to weigh on near-term sales. The company also cited potential supply-chain disruption and delayed qualification of its high-volume packaging line, then projected for 2021.
- DoD opportunity: DSUVIA was added to the Department of Defense Joint Deployment Formulary. The U.S. Army awarded an initial contract of up to $3.6 million over four years for a DoD-sponsored study; future DoD orders were described as uncertain and potentially irregular.
- Management outlook: Management said existing capital resources were expected to fund operations for at least the next 12 months, but not until the business can generate sufficient revenue to sustain operations. The company expected continued losses and negative operating cash flow. It projected that the packaging line could contribute to significantly lower cost of goods sold in 2022 and beyond. No quantified revenue or earnings guidance was provided.
- Key risks: Continued losses and need for additional capital; COVID-related commercial and supply constraints; dependence on successful DSUVIA adoption; loss of the Grünenthal partner and royalty uncertainty; delayed or unsuccessful U.S. Zalviso NDA resubmission amid evolving FDA opioid guidance; opioid regulation, safety and REMS requirements; and manufacturing and single-source supply risks. DZUVEO’s European authorization could lapse under the EMA sunset clause if it is not commercially launched by June 2021, absent an exemption.
- The filing reported no pending legal proceedings believed likely to have a material adverse effect, no defaults upon senior securities, and effective disclosure controls as of quarter-end.
Important facts for investors to verify
- Confirm the issuer: the provided filing is AcelRx Pharmaceuticals, Inc., not Talphera, Inc.
- Track post-termination arrangements for Zalviso, including any replacement European license, supply obligations and effects on royalty-monetization payments.
- Assess cash runway against operating cash burn, debt service, the $5 million minimum unrestricted-cash covenant, and the availability and dilution effects of further financing.
- Monitor DSUVIA sales excluding irregular DoD purchases, and the performance and economics of the La Jolla and Zimmer Biomet Dental arrangements.
- Check progress on the packaging line and any FDA decision or timing update concerning Zalviso NDA resubmission.